"These guidelines address the unique needs of diverse groups typically underrepresented in clinical trials, and highlight the importance of a multidisciplinary approach."
Incyte's povorcitinib, an oral JAK1 inhibitor, demonstrates promising results in phase 3 trials for hidradenitis suppurativa, potentially offering a new alternative treatment option.
Reuters
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
COVID-19 infection significantly increases autoimmune blistering disease risk, while vaccination appears protective, researchers report in a study analyzing 112 million patient records